Scholarlink

<p>Mutations in chromatin-regulating genes play a critical role in the pathogenesis of myelodysplastic neoplasia (MDS) and acute myeloid leukemia (AML), as genetic mutations affecting chromatin structure and function are key drivers of these hematologic malignancies. Central to the discussion are key emerging genes such as <i>ASXL1</i>, <i>SRSF2</i>, and <i>EZH2</i>, which are recognized as adverse prognostic markers. Mutations in these genes, coupled with subsequent alterations in epigenetic mechanisms, disrupt normal gene expression by impairing histone modification and RNA splicing processes. Specifically, mutations in ASXL1 enhance removal of ubiquitylation at histone H2AK119, leading to altered gene expression and impaired hematopoietic stem cell differentiation. Mutations in SRSF2, an RNA splicing factor, alter RNA-binding specificity, inducing aberrant splicing of key genes such as <i>EZH2</i>. Loss-of-function mutations in EZH2 disrupt PRC2-mediated transcriptional repression, promoting leukemic progression. However, while the effects of these mutations are understood, treatment options for high-risk patients remain limited. Emerging strategies, such as venetoclax combined with hypomethylating agents, showing promise in mitigating the poor prognosis associated with these mutations. This review consolidates recent findings on these epigenetic regulators and their interactions, providing insights into the multifaceted mechanisms of leukemogenesis in the interest of inspiring targeted therapeutic strategies and bridging extant treatment gaps for MDS/AML.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

The role of ASXL1, SRSF2, and EZH2 mutations in chromatin dysregulation of myelodysplastic neoplasia and acute myeloid leukemia

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年6月25日

查看全文
  • Hosang Yu,
  • Junshik Hong,
  • Dong-Yeop Shin,
  • Chul-Hwan Lee

摘要

Mutations in chromatin-regulating genes play a critical role in the pathogenesis of myelodysplastic neoplasia (MDS) and acute myeloid leukemia (AML), as genetic mutations affecting chromatin structure and function are key drivers of these hematologic malignancies. Central to the discussion are key emerging genes such as ASXL1, SRSF2, and EZH2, which are recognized as adverse prognostic markers. Mutations in these genes, coupled with subsequent alterations in epigenetic mechanisms, disrupt normal gene expression by impairing histone modification and RNA splicing processes. Specifically, mutations in ASXL1 enhance removal of ubiquitylation at histone H2AK119, leading to altered gene expression and impaired hematopoietic stem cell differentiation. Mutations in SRSF2, an RNA splicing factor, alter RNA-binding specificity, inducing aberrant splicing of key genes such as EZH2. Loss-of-function mutations in EZH2 disrupt PRC2-mediated transcriptional repression, promoting leukemic progression. However, while the effects of these mutations are understood, treatment options for high-risk patients remain limited. Emerging strategies, such as venetoclax combined with hypomethylating agents, showing promise in mitigating the poor prognosis associated with these mutations. This review consolidates recent findings on these epigenetic regulators and their interactions, providing insights into the multifaceted mechanisms of leukemogenesis in the interest of inspiring targeted therapeutic strategies and bridging extant treatment gaps for MDS/AML.